![](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1645090592/argenx_news_2020-10-21.jpg/argenx_news_2020-10-21.jpg?VersionId=k4r9i8YjFgVUWIKxpzMNvMIh.qFRWS0J)
Argenx's Vyvgart holds its own against AstraZeneca rivals in myasthenia gravis clash
Following last week’s R&D day, argenx continues to demonstrate that its flagship drug, FcRn inhibitor Vyvgart, has plenty of room to grow in its inaugural generalized myasthenia gravis (gMG) indication. For 2024’s second quarter, infused Vyvgart and …